# Press release

*U-Protein Express receives US patent covering a method on protein sequencing using Lys-N.*

Utrecht, The Netherlands, December 25th 2012 – U-Protein Express B.V., a dedicated service provider in the field of recombinant protein and antibody production based in the Netherlands, announced that it has received its US patent covering a method on protein sequencing. U-Protein Express has been granted the US patent covering the use of its unique Lys-N protease for dedicated protein sequencing from a patent family that already comprises a number of issued European patents.

This further strengthens the position of the company that already is the unique supplier of recombinant LysN for protein sequencing by mass spectroscopy. The company seeks partners to out-license the technology for service providers in the sequence arena.

About LysN based protein sequencing. LysN is a metalloendopeptidase that hydrolyses the peptide bond specifically at the N-terminal site of lysine residues. In contrast to trypsin, LysN has a broad thermo-, detergent- and pH stability. This makes the enzyme extremely suitable for protein sequencing by mass-spectroscopy using ETD and CID. In addition, more homogenous ionization fragments are obtained compared to proteolytic fragments generated by trypsin and LysC, resulting in mass spectra that are easy to interpret.

About U-Protein Express. U-Protein Express is a dedicated contract research organization and offers various services. Fully post translational modified mammalian proteins can be produced via the r-PEx technology. In addition, *E. coli* and *Pichia pastoris* expression platforms are available for the production of more simple proteins. Produced recombinant proteins are purified in house by state-of-the-art purification technology. Main customers are academia, biotech- and pharma companies.

For more information on U-Protein Express B.V. or on the Lys-N protein sequencing technology please contact Dr. Martin Hessing, at M.Hessing@U-ProteinExpress.com.